OncoMatch/Sarcoma/NTRK fusion (ETV6::NTRK3)

SarcomaNTRK fusion (ETV6::NTRK3) Clinical Trials

NTRK fusions occur in several sarcoma subtypes including infantile fibrosarcoma (ETV6::NTRK3, ~90% prevalence), lipofibromatosis-like neural tumor, and NTRK-rearranged spindle cell neoplasms. Larotrectinib and entrectinib are FDA-approved for NTRK fusion-positive solid tumors regardless of histology, with high response rates in NTRK-driven sarcomas. Trials investigate next-generation NTRK inhibitors overcoming resistance, pediatric-focused NTRK basket studies, and sequential NTRK inhibitor strategies.